 Benjamin Van Court
Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 16 | 2024 | 562 | 2.410 |
Why?
| | Ephrin-B2 | 6 | 2024 | 45 | 0.880 |
Why?
| | Receptor, EphB4 | 5 | 2024 | 33 | 0.840 |
Why?
| | Spiral Cone-Beam Computed Tomography | 1 | 2023 | 5 | 0.800 |
Why?
| | Tumor Microenvironment | 12 | 2024 | 735 | 0.540 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2023 | 292 | 0.540 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2022 | 389 | 0.520 |
Why?
| | Pancreatic Neoplasms | 5 | 2023 | 927 | 0.470 |
Why?
| | STAT3 Transcription Factor | 3 | 2022 | 207 | 0.340 |
Why?
| | Gamma Rays | 2 | 2021 | 56 | 0.330 |
Why?
| | Radiation Tolerance | 2 | 2021 | 103 | 0.290 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2021 | 199 | 0.290 |
Why?
| | Mice | 19 | 2024 | 18365 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 154 | 0.280 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2021 | 930 | 0.260 |
Why?
| | Interleukin-2 | 2 | 2023 | 437 | 0.220 |
Why?
| | Immunotherapy | 4 | 2023 | 657 | 0.220 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3550 | 0.210 |
Why?
| | Animals | 20 | 2024 | 38109 | 0.210 |
Why?
| | PPAR alpha | 1 | 2024 | 54 | 0.210 |
Why?
| | Oleic Acid | 1 | 2024 | 42 | 0.210 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2024 | 40 | 0.200 |
Why?
| | Interleukin-7 | 1 | 2024 | 65 | 0.200 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2023 | 30 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2024 | 220 | 0.190 |
Why?
| | Cell Proliferation | 5 | 2021 | 2499 | 0.190 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Radioimmunotherapy | 1 | 2021 | 25 | 0.170 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 239 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2021 | 35 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 77 | 0.160 |
Why?
| | Receptors, Complement | 1 | 2021 | 125 | 0.160 |
Why?
| | Cell Movement | 3 | 2021 | 965 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 116 | 0.160 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 74 | 0.160 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 72 | 0.150 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 79 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 151 | 0.150 |
Why?
| | Infratentorial Neoplasms | 1 | 2019 | 71 | 0.140 |
Why?
| | Receptor, EphB3 | 1 | 2018 | 4 | 0.140 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 919 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 29 | 0.140 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 80 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 173 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 548 | 0.140 |
Why?
| | Software | 1 | 2023 | 692 | 0.130 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 109 | 0.130 |
Why?
| | Membrane Proteins | 2 | 2021 | 1167 | 0.130 |
Why?
| | Morpholines | 1 | 2018 | 129 | 0.130 |
Why?
| | Aminopyridines | 1 | 2018 | 127 | 0.130 |
Why?
| | Ependymoma | 1 | 2019 | 176 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2024 | 917 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2024 | 4569 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2021 | 499 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 345 | 0.130 |
Why?
| | Glioblastoma | 1 | 2020 | 353 | 0.120 |
Why?
| | Signal Transduction | 5 | 2024 | 5233 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 241 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 883 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3415 | 0.110 |
Why?
| | Tumor Burden | 3 | 2021 | 322 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2022 | 931 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1462 | 0.100 |
Why?
| | Mice, Nude | 3 | 2020 | 688 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2022 | 1268 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1253 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 642 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1322 | 0.100 |
Why?
| | Apoptosis | 4 | 2021 | 2430 | 0.090 |
Why?
| | Humans | 20 | 2024 | 144957 | 0.090 |
Why?
| | Survival Rate | 3 | 2021 | 2092 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1322 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2021 | 3125 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5997 | 0.080 |
Why?
| | Radiotherapy | 2 | 2019 | 206 | 0.070 |
Why?
| | Prognosis | 3 | 2021 | 4293 | 0.070 |
Why?
| | Fenofibrate | 1 | 2024 | 28 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 177 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 695 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2022 | 173 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 68 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 23 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 42 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 264 | 0.040 |
Why?
| | Fatty Acids | 1 | 2024 | 452 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 132 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 202 | 0.040 |
Why?
| | Complement C3 | 1 | 2021 | 191 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 88 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 252 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 372 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 144 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 509 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 469 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 223 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2021 | 437 | 0.030 |
Why?
| | Immunomodulation | 1 | 2018 | 101 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1129 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 476 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 434 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1733 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 966 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 846 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1173 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1718 | 0.030 |
Why?
| | Female | 5 | 2021 | 78376 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1095 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2852 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1490 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1982 | 0.020 |
Why?
| | Neutrophils | 1 | 2019 | 1134 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3164 | 0.020 |
Why?
| | Macrophages | 1 | 2019 | 1511 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7183 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4275 | 0.020 |
Why?
| | Child | 1 | 2019 | 22657 | 0.010 |
Why?
|
|
Van Court's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|